Your training partner runs 500 mg of testosterone per week and keeps his hairline. You run 200 mg and start shedding in week 3. The difference is not your protocol — it is your genes. Hair loss on androgenic compounds is almost entirely determined by genetic sensitivity to dihydrotestosterone (DHT), and understanding that sensitivity separates preventable shedding from inevitable baldness.
The DHT Mechanism: Testosterone's More Potent Metabolite
Testosterone is converted to DHT by the enzyme 5α-reductase, which is concentrated in the scalp, prostate, and skin. DHT binds the androgen receptor with roughly 2-4 times the affinity of testosterone itself, making it a much more potent signal in tissues where 5α-reductase is active.
In the scalp, DHT binds to androgen receptors in dermal papilla cells — the cells that regulate hair follicle growth. In genetically sensitive individuals, this binding triggers a progressive shortening of the anagen (growth) phase and miniaturization of the follicle. Each hair cycle produces a thinner, shorter hair until the follicle eventually stops producing visible hair entirely.
The genetic key is a sequence in the androgen receptor gene called the CAG repeat. Shorter CAG repeats produce a more sensitive androgen receptor — the same DHT level produces a stronger signal. Men with shorter CAG repeats are significantly more likely to develop male pattern baldness, both naturally and under AAS. This is also why some men lose hair on 200 mg of testosterone while others keep their hair on 500 mg. It is not fairness — it is CAG repeat length.
Compound Impact on Hair: Androgenic Affinity Ranking
Not all AAS compounds affect hair equally. The key variable is the compound's androgenic binding affinity — how strongly it binds the androgen receptor. Compounds that are structural derivatives of DHT (like masteron and winstrol) have high androgenic affinity. Compounds with a modified structure that reduces androgenic binding (like nandrolone and primobolan) are significantly milder.
Compound Androgenic Impact on Hair
| Marker | Impact Level | Mechanism |
|---|---|---|
| Trenbolone | Highest (severe shedding) | 5× AR affinity of testosterone |
| Masteron (Drostanolone) | Very High | DHT derivative, no 5α-reduction needed |
| Winstrol (Stanozolol) | Very High | DHT derivative, oral, no aromatization |
| Testosterone | Moderate-High | Converted to DHT via 5α-reductase |
| Anavar (Oxandrolone) | Low-Moderate | DHT derivative with modified structure |
| Primobolan | Low | Weak AR binding, DHT derivative |
| Nandrolone | Low | Converts to weak androgen (DHN), not DHT |
Note that nandrolone actually converts to dihydronandrolone (DHN), which is a weak androgen, rather than DHT. This makes nandrolone one of the mildest compounds for hair — and a common choice for users who are genetically predisposed to hair loss but still want to run a compound cycle. However, individual response still varies, and some users report shedding on nandrolone despite the favorable pharmacology.
Blood Markers Relevant to Hair Loss
Three blood markers provide useful information about your hair loss risk and the appropriate intervention strategy:
DHT serum levels — While DHT is primarily a local (paracrine) hormone, serum DHT correlates with scalp DHT activity in most individuals. A baseline DHT measurement before starting compounds tells you where you start. On AAS, elevated DHT confirms that 5α-reductase is active. If you are shedding and your DHT is in range despite high testosterone, the shedding is likely driven by direct AR binding from the compound itself rather than from converted DHT.
SHBG — Low SHBG means more free (unbound) testosterone is available for 5α-reductase conversion to DHT. Androgenic compounds suppress SHBG pharmacologically, which increases free androgen fractions. A low SHBG on cycle (below 15 nmol/L) amplifies the amount of testosterone available for DHT conversion, potentially accelerating hair loss in sensitive individuals.
Ferritin and iron status — This is the most overlooked marker in hair loss. Ferritin below 40 ng/mL is associated with telogen effluvium — a form of shedding caused by nutrient deficiency rather than androgen activity. If you are losing hair and your ferritin is low, correcting iron status may reduce shedding significantly, even without addressing the androgen component. Check ferritin, serum iron, TIBC, and transferrin saturation before assuming DHT is the only factor.
Prevention and Intervention Options
The most effective intervention is compound selection. If you know you are genetically sensitive (family history of MPB, known short CAG repeats), choosing low-androgen compounds like nandrolone and primobolan over trenbolone and masteron will have a larger impact on hair preservation than any medication.
Finasteride (1 mg/day) blocks type II 5α-reductase, reducing DHT conversion by approximately 70%. For TRT patients, finasteride effectively prevents testosterone from converting to DHT in the scalp. The trade-off: serum DHT drops, and some users experience a compensatory rise in estradiol because more testosterone is available for aromatization. If you are prone to high E2 symptoms, monitor estradiol 4-6 weeks after starting finasteride.
Dutasteride (0.5 mg/day) blocks both type I and type II 5α-reductase, reducing DHT by over 90%. It is more effective for hair preservation but carries a higher risk of side effects, including a more pronounced E2 shift. Dutasteride's half-life is roughly 5 weeks, so side effects persist longer after discontinuation.
Hair Loss vs. Compound Selection
Minoxidil (5% topical, once or twice daily) prolongs the anagen phase and increases blood flow to the follicle. It works independently of androgen signaling, so it can be used alongside any compound. Results take 3-6 months to appear, and shedding often increases in the first 4-6 weeks as the follicle cycle resets. This initial shed is not a sign that hair loss is worsening — it is the drug working.
When to Worry: Diffuse Thinning vs. MPB Pattern
Not all shedding on AAS is male pattern baldness (MPB). The pattern of hair loss tells you whether androgens are driving it or another factor is involved.
MPB pattern: Recession at the temples and thinning at the crown. This is androgen-driven and predictable. It will progress if you continue using androgenic compounds without intervention. It is often not fully reversible, even after stopping compounds.
Diffuse thinning: Hair loss spread evenly across the scalp, without a clear MPB pattern. This can be caused by telogen effluvium (stress, nutrient deficiency, rapid hormone shifts), thyroid dysfunction, or iron deficiency. Diffuse thinning is frequently reversible once the underlying cause is addressed. If you notice clumps of hair in the shower but no clear recession pattern, check ferritin, TSH, and free T3 before reaching for finasteride.